Four decades of discovery in breast cancer research and treatment - an interview with V. Craig Jordan

International Journal of Developmental Biology

Volumn 55, Issue 7-9, 2011, Pages 703-712

  Poirot, Marc ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

Acquired antihormone resistance; Estradiol induced apoptosis; Estrogen; Nonsteroidal antiestrogen; Raloxifene; Selective estrogen receptor modulator (SERM); Tamoxifen

Indexed keywords

AFIMOXIFENE; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTROGEN RECEPTOR; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ACHIEVEMENT; ADJUVANT THERAPY; AGING; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; ENDOMETRIUM CANCER; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MENOPAUSE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STROKE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENGLAND; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MICE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 82555185372     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.113418mp     Document Type: Article

References (41)

1. ARIAZI E.A., CUNLIFFE H.E., LEWIS-WAMBI J.S., SLIFKER M.J., WILLIS A.L., RAMOS P., TAPIA C., KIM H.R., YERRUM S., SHARMA C.G.N., NICOLAS E., BALAGURUNATHAN Y., ROSS E.A. and JORDAN V.C. (in press). Estrogen Induces Apoptosis in Estrogen Deprivation-resistant Breast Cancer via Stress Responses as Identified by Global Gene Expression. Proc Natl Acad Sci USA.
2. CUMMINGS S.R., ECKERT S., KRUEGER K.A., GRADY D., POWLES T.J., CAULEY J.A., NORTON L., NICKELSEN T., BJARNASON N.H., MORROW M., LIPPMAN M.E., BLACK D., GLUSMAN J.E., COSTA A. and JORDAN V.C. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189-2197.
3. CUMMINGS S.R., ENSRUD K., DELMAS P.D., REID D.M., GOLDSTEIN S., SRIRAM U., LEE A., THOMPSON J., ARMSTRONG R.A., THOMPSON D.D., POWLES T., ZANCHETTA J., KENDLER D., NEVEN P. and EASTELL R. (2010). Lasofoxifene in postmenopausal women with osteoporosis. New Engl J Med 362: 686-696.
4. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP (EBCTCG). (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
5. GOTTARDIS M.M. and JORDAN V.C. (1987). The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020-4024.
6. GOTTARDIS M.M. and JORDAN V.C. (1988). Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187.
7. GOTTARDIS M.M., ROBINSON S.P., SATYASWAROOP P.G. and JORDAN V.C. (1988). Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48: 812-815.
8. HADDOW A. (1970). David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 26: 737-754.
9. JORDAN V.C. and KOERNER S. (1975). Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205-206.
10. JORDAN V.C. (1976). Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 12: 419-424.
11. JORDAN V. C, COLLINS M.M., ROWSBY L. and PRESTWICH G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305-316.
12. JORDAN V.C. (1978). Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev on Endocr Relat Cancer 49-55.
13. JORDAN V.C., DIX C.J. and ALLEN K.E. (1979). The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In Adjuvant Therapy of Cancer II (Eds. S.E. Salmon and S. E. Jones). Grune & Stratton Inc., Philadelphia, pp. 19-26.
14. JORDAN V.C. and ALLEN K.E. (1980). Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239-251.
15. JORDAN V.C. and LIEBERMAN M.E. (1984). Estrogen-stimulated prolactin synthesis in vitro classification of agonists, partial agonist and antagonist actions based on structure. Mol Pharm 26: 279-285.
16. JORDAN V.C. (1984). Biochemical pharmacology of antiestrogen action. Pharm Rev 36: 245-276.
17. JORDAN V.C., PHELPS E. and LINDGREN J.U. (1987). Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31-35.
18. JORDAN V.C. (1988). The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat 11: 197-209.
19. JORDAN V.C. (1995). What if tamoxifen (ICI 46,474) had been found to produce liver tumors in rats in 1973? Ann Oncol 6: 29-43.
20. JORDAN V.C. (2001). Selective Estrogen Receptor Modulation: a personal perspective. (Perspectives in Cancer Research). Cancer Res 61: 5683-5687.
21. JORDAN V.C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2: 205-213.
22. th Anniversary Edition British Journal of Pharmacology Special Issue. Tamoxifen (ICI 46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147: S269-S276.
23. JORDAN V.C. (2007). Chemoprevention of Breast Cancer with Selective Oestrogen Receptor Modulators. Nat Rev Cancer 7: 46-53.
24. JORDAN V.C. (2008 a). Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44: 30-38.
25. JORDAN V.C. (2008 b). The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? J Clin Oncol 26: 3073-3082.
26. JORDAN V.C. (2009). A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69: 1243-1254.
27. JORDAN V.C. and FORD L.S. (2011). Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A "New" Biology of Estrogen-Induced Apoptosis. Cancer Prev Res 4: 633-637.
28. LA CROIX A.Z., CHLEBOWSKI R.T., MANSON J.E., ARAGAKI A.K., JOHNSON K.C., MARTIN L., MARGOLIS K.L., STEFANICK M.L., BRZYSKI R., CURB J.D., HOWARD B.V., LEWIS C.E. and WACTAWSKI-WENDE, J. (2011). Health outcomes after stopping conjugated equines estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 205: 1305-1314.
29. LEVENSON A.S. and JORDAN V.C. (1998). The key to the antiestrogenic mechanism of raloxifene is Amino Acid 351 (Asp) in the estrogen receptor. Cancer Res 58: 1872-1875.
30. LEWIS J.S., MEEKE K., OSIPO C., ROSS E.A., KIDAWI N., LI Y., BELL E., CHANDEL N.S. and JORDAN V.C. (2005). Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759.
31. LIEBERMAN M.E., JORDAN V.C., FRITSCH M., SANTOS M.A. and GORSKI J. (1983 a). Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258: 4734-4740.
32. LIEBERMAN M.E., GORSKI J. and JORDAN V.C. (1983 b). An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 258: 4741-4745.
33. LIU H., LEE E.S., DE LOS REYES A., ZAPF J.W. and JORDAN V.C. (2001). Silencing and reactivation of the selective estrogen receptor modulator (SERM)-ER alpha complex. Cancer Res 61: 3632-3639.
34. LIU H., PARK W., BENTREM D.J., MCKIAN K.P., DE LOS REYES A., MACGREGOR-SCHAFER J., ZAPF J. and JORDAN V.C. (2002). Structure-function relationships of the raloxifene-estrogen receptor alpha complex for regulating transforming growth factor alpha expression in breast cancer cells. J Biol Chem 277: 9189-9198.
35. LOVE R.R., MAZESS R.B., BARDEN H.S., EPSTEIN S., NEWCOMB P.A., JORDAN V.C., CARBONE P.P. and DEMETS D.L. (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl J Med 326: 852-856.
36. MACGREGOR-SCHAFER J.I., LIU H., BENTREM D., ZAPF J. And JORDAN V.C. (2000). Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex by substituting glycine for aspartate at amino acid 351. Cancer Res 60: 5097-5105.
37. VOGEL V.G., COSTANTINO J.P., WICKERHAM D.L., CRONIN W.M., CECCHINI R.S., ATKINS J.N., BEVERS T.B., FEHRENBACHER L., PAJON E.R., WADE J.L., ROBIDOUX A., MARGOLESE R.G., JAMES J., LIPPMAN S.M., RUNOWICZ C.D., GANZ P.A., REIS S.E., MCCASKILL-STEVENS W., FORD L.G., JORDAN V.C. and WOLMARK N. (2006). The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 295: 2727-2741.
38. VOGEL V.G., COSTANTINO J.P., WICKERHAM D.L., CRONIN W.M., CECCHINI R.S., ATKINS J.N., BEVERS T.B., FEHRENBACHER L., PAJON E.R., WADE J.L., ROBIDOUX A., MARGOLESE R.G., JAMES J., RUNOWICZ C.D., GANZ P.A., REIS S.E., MCCASKILL-STEVENS W., FORD L.G., JORDAN V.C. and WOLMARK N. (2010). Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prev Res 3: 696-706.
39. WOLF D.M. and JORDAN V.C. (1993). A laboratory model to explain the survival advantage observed in patients taking adjuvent tamoxifen therapy. Recent Results Cancer Res 127: 23-33.
40. WOLF D.M. and JORDAN V.C. (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31: 129-138.
41. YAO K., LEE E.S., BENTREM D.J., ENGLAND G., SCHAFER J.I.M., O'REGAN R. and JORDAN V.C. (2000). Antitumor action of physiologic estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036.